UroGen Pharma Shares Results From 5-Year Follow-Up Study On Olympus
Five-year Olympus follow-up data published in Therapeutic Advances in Urology reinforce the long-term durability of response with JELMYTOResults demonstrate sustained disease control through extended follow-up among
Share
Why It Matters
UroGen's Olympus medicine showed it keeps working for five years. This long-term success suggests the treatment is reliable and durable.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.